News

July 22, 2014 — Boston Scientific announced it received U.S. Food and Drug Administration (FDA) approval for the Rebel platinum chromium coronary stent system, the company's latest-generation bare...

stentys, stent, self-apposing stent

Stentys has announced the publication of an article in the Journal of the American College of Cardiology (JACC) entitled, "Causes of Early Stent Thrombosis in Patients Presenting with Acute...

July 15, 2014 — Micell Technologies Inc. announced the United States Patent and Trademark Office (USPTO) has issued a patent related to Micell's technology for enhancing the performance of medical...

July 10, 2014 — 480 Biomedical announced it has been awarded Phase II funding from the National Heart, Lung, and Blood Institute (NHLBI) to continue the development of a bioresorbable, self-...

A big fly in the ointment for widespread adoption of many new technologies is cost. In today’s cost-conscience environment of healthcare reform, there needs to be a clear, quantifiable...

OrbusNeich Patient Enrollment Completion REMEDEE Registry Combo Stent

OrbusNeich announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal...

Medtronic announced it is purchasing Covidien in a cash-and-stock deal for $42.9 billion. Once the transaction is completed, Medtronic will have significantly advanced its position as a premier...

June 10, 2014 — Ariad Pharmaceuticals Inc. and Medinol Ltd. earlier this year initiated two registration trials of Medinol’s NIRsupreme ridaforolimus-eluting coronary stent system incorporating...

Strokes kill nearly 130,000 Americans every year, according to the Centers for Disease Control and Prevention. Because approximately 30 percent of strokes are caused by blockages in the carotid...

May 23, 2014 — Stentys presented final results from the APPOSITION IV study of its new self-apposing sirolimus-eluting stent (SES) during the Hotline session at the EuroPCR conference in Paris.

Elixir Medical Corp. DESolve 100 CE mark

Elixir Medical Corp. received CE mark approval for its DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System.

InspireMD Inc. initiated a Voluntary Field Action (VFA) following recent reports of MGuard Prime EPS (embolic protection systems), stent dislodgements. 

Boston Scientific Promus Premier Drug Eluting Stent

Boston Scientific Corp. has launched the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan. This advanced drug-eluting stent (DES) technology system recently...

April 16, 2014 — Abbott announced it has completed enrollment of three clinical trials to support approvals of the company's Absorb bioresorbable vascular scaffold (BVS) in the United States,...

SCAI ACC.14 Choosing Wisely Campaign Tests Treatments to Avoid Cath Lab

The Society for Cardiovascular Angiography & Interventions (SCAI) issued a list of five specific, evidence-based recommendations that should be avoided in the care of patients who have, or are...

Biolimus Everolimus Stent Clinical Trial ACC.14

A new stent covered with biodegradable coating continues to show statistical equivalence to Japan’s market leader in cumulative second-year data and subgroup analyses, according to research from...

FDA Abbott Supera Self-Expanding Stent Peripheral Artery Disease

The U.S. Food and Drug Administration (FDA) approved Abbott’s Supera Peripheral Stent System to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD...

Terumo Corp. Arterial Remodeling Technologies Bioresorbable Coronary Stent

Privately held Arterial Remodeling Technologies (ART) signed a structured buyout agreement with Terumo Corp. Under the agreement, ART and Terumo Corp. will collaborate in the development of a drug...

InspireMD Inc. has enrolled the first patient into the CARENET (CARotid Embolic protection study using microNET) multi-center European...

Medtronic Endeavor Stents Drug-eluting Antiplatelet Therapy Clinical Study

Patients with coronary artery disease who received an Endeavor or Resolute drug-eluting stent from Medtronic Inc. and subsequently interrupted their dual ...